How does β-cell tolerance contribute to the protective effects of diabetes following induced mixed chimerism in autoimmune diabetes?

Diabetes

Volumn 63, Issue 6, 2014, Pages 1855-1857

  Wong, F Susan ^a  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL ACTIVATING FACTOR; CELL SURFACE IMMUNOGLOBULIN; GLUCOSE; MONOCLONAL ANTIBODY;

AUTOIMMUNE DISEASE; AUTOLOGOUS STEM CELL TRANSPLANTATION; B LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHIMERA; GLUCOSE BLOOD LEVEL; HUMAN; IMMUNOLOGICAL TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; NONMYELOABLATIVE CONDITIONING; NOTE; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; ANIMAL; FEMALE; HISTOCOMPATIBILITY; IMMUNOLOGY; SPLEEN;

ANIMALS; ANTIBODIES, MONOCLONAL; CHIMERISM; FEMALE; MAJOR HISTOCOMPATIBILITY COMPLEX; SPLEEN; TRANSPLANTATION CHIMERA;

EID: 84901340847     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db14-0327     Document Type: Note

References (18)

1. Keenan HA, Sun JK, Levine J, et al. Residual insulin production and pancreatic ß-cell turnover after 50 years of diabetes: Joslin Medalist Study. Diabetes 2010;59:2846-2853
2. Oram RA, Jones AG, Besser RE, et al. The majority of patients with longduration type 1 diabetes are insulin microsecretors and have functioning beta cells. Diabetologia 2014;57:187-191
3. Couri CE, Oliveira MC, Stracieri AB, et al. C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 2009;301: 1573-1579
4. Voltarelli JC, Couri CE, Stracieri AB, et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 2007;297:1568-1576
5. Staeva TP, Chatenoud L, Insel R, Atkinson MA. Recent lessons learned from prevention and recent-onset type 1 diabetes immunotherapy trials. Diabetes 2013;62:9-17
6. Herold KC, Hagopian W, Auger JA, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002;346:1692-1698
7. Keymeulen B, Vandemeulebroucke E, Ziegler AG, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005;352: 2598-2608
8. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, et al.; Type 1 Diabetes TrialNet Anti-CD20 Study Group. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009;361:2143-2152
9. Pescovitz MD, Greenbaum CJ, Bundy B, et al.; Type 1 Diabetes TrialNet Anti-CD20 Study Group. B-lymphocyte depletion with rituximab and β-cell function: two-year results. Diabetes Care 2014;37:453-459
10. Zhang C, Todorov I, Lin CL, et al. Elimination of insulitis and augmentation of islet beta cell regeneration via induction of chimerism in overtly diabetic NOD mice. Proc Natl Acad Sci USA 2007;104:2337-2342 (Pubitemid 46391398)
11. Wang M, Racine JJ, Song X, et al. Mixed chimerism and growth factors augment beta cell regeneration and reverse late-stage type 1 diabetes. Sci Transl Med 2012;4:133ra159
12. Racine JJ, Wang M, Zhang M, Zeng D. Induction of mixed chimerism depletes pre-existing and de novo2developed autoreactive B cells in autoimmune NOD mice. Diabetes 2014;63:2051-2062
13. Racine J, Wang M, Zhang C, et al. Induction of mixed chimerism with MHC-mismatched but not matched bone marrow transplants results in thymic deletion of host-type autoreactive T-cells in NOD mice. Diabetes 2011;60:555- 564
14. Daniels GH, Vladic A, Brinar V, et al. Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis. J Clin Endocrinol Metab 2014;99:80-89
15. Lanzavecchia A. Antigen-specific interaction between T and B cells. Nature 1985;314:537-539 (Pubitemid 15124262)
16. Constant S, Schweitzer N, West J, Ranney P, Bottomly K. B lymphocytes can be competent antigen-presenting cells for priming CD4+ T cells to protein antigens in vivo. J Immunol 1995;155:3734-3741
17. Mariño E, Tan B, Binge L, Mackay CR, Grey ST. B-cell cross-presentation of autologous antigen precipitates diabetes. Diabetes 2012;61:2893-2905
18. Hu CY, Rodriguez-Pinto D, Du W, et al. Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. J Clin Invest 2007; 117:3857-3867 (Pubitemid 350224095)